vs

Side-by-side financial comparison of Commerce.com, Inc. (CMRC) and RIGEL PHARMACEUTICALS INC (RIGL). Click either name above to swap in a different company.

Commerce.com, Inc. is the larger business by last-quarter revenue ($89.5M vs $69.8M, roughly 1.3× RIGEL PHARMACEUTICALS INC). RIGEL PHARMACEUTICALS INC runs the higher net margin — 384.0% vs -9.3%, a 393.4% gap on every dollar of revenue. On growth, RIGEL PHARMACEUTICALS INC posted the faster year-over-year revenue change (21.2% vs 2.9%). Over the past eight quarters, RIGEL PHARMACEUTICALS INC's revenue compounded faster (53.7% CAGR vs 5.5%).

SPS Commerce, Inc. is a technology and application software company based in the United States that provides cloud-based supply chain management software. The company's headquarters are located in Minneapolis, Minnesota, but it also has a US office in New Jersey, and international locations in Amsterdam, Beijing, Breukelen, Hong Kong, Kyiv, Melbourne, Montpellier, Sydney, and Toronto.

Rigel Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing targeted small molecule therapies for autoimmune, inflammatory, and hematologic diseases. Its approved flagship product treats adult immune thrombocytopenia, with primary operations and core markets in the United States, addressing unmet medical needs for underserved patient groups.

CMRC vs RIGL — Head-to-Head

Bigger by revenue
CMRC
CMRC
1.3× larger
CMRC
$89.5M
$69.8M
RIGL
Growing faster (revenue YoY)
RIGL
RIGL
+18.3% gap
RIGL
21.2%
2.9%
CMRC
Higher net margin
RIGL
RIGL
393.4% more per $
RIGL
384.0%
-9.3%
CMRC
Faster 2-yr revenue CAGR
RIGL
RIGL
Annualised
RIGL
53.7%
5.5%
CMRC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CMRC
CMRC
RIGL
RIGL
Revenue
$89.5M
$69.8M
Net Profit
$-8.4M
$268.1M
Gross Margin
78.3%
91.5%
Operating Margin
-7.4%
33.2%
Net Margin
-9.3%
384.0%
Revenue YoY
2.9%
21.2%
Net Profit YoY
-250.0%
1769.2%
EPS (diluted)
$-0.11
$14.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CMRC
CMRC
RIGL
RIGL
Q4 25
$89.5M
$69.8M
Q3 25
$86.0M
$69.5M
Q2 25
$84.4M
$101.7M
Q1 25
$82.4M
$53.3M
Q4 24
$87.0M
$57.6M
Q3 24
$83.7M
$55.3M
Q2 24
$81.8M
$36.8M
Q1 24
$80.4M
$29.5M
Net Profit
CMRC
CMRC
RIGL
RIGL
Q4 25
$-8.4M
$268.1M
Q3 25
$-2.2M
$27.9M
Q2 25
$-8.4M
$59.6M
Q1 25
$-353.0K
$11.4M
Q4 24
$-2.4M
$14.3M
Q3 24
$-7.0M
$12.4M
Q2 24
$-11.3M
$-1.0M
Q1 24
$-6.4M
$-8.2M
Gross Margin
CMRC
CMRC
RIGL
RIGL
Q4 25
78.3%
91.5%
Q3 25
78.4%
93.2%
Q2 25
79.0%
95.6%
Q1 25
79.4%
91.7%
Q4 24
77.6%
89.9%
Q3 24
76.3%
85.5%
Q2 24
75.8%
92.4%
Q1 24
77.1%
93.1%
Operating Margin
CMRC
CMRC
RIGL
RIGL
Q4 25
-7.4%
33.2%
Q3 25
-0.5%
40.9%
Q2 25
-8.0%
60.1%
Q1 25
-2.9%
23.9%
Q4 24
-0.9%
28.9%
Q3 24
-23.0%
25.4%
Q2 24
-16.5%
1.2%
Q1 24
-10.2%
-23.6%
Net Margin
CMRC
CMRC
RIGL
RIGL
Q4 25
-9.3%
384.0%
Q3 25
-2.6%
40.2%
Q2 25
-9.9%
58.6%
Q1 25
-0.4%
21.5%
Q4 24
-2.7%
24.9%
Q3 24
-8.4%
22.5%
Q2 24
-13.8%
-2.8%
Q1 24
-8.0%
-27.9%
EPS (diluted)
CMRC
CMRC
RIGL
RIGL
Q4 25
$-0.11
$14.11
Q3 25
$-0.03
$1.46
Q2 25
$-0.10
$3.28
Q1 25
$0.00
$0.63
Q4 24
$-0.03
$0.82
Q3 24
$-0.09
$0.70
Q2 24
$-0.15
$-0.06
Q1 24
$-0.08
$-0.47

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CMRC
CMRC
RIGL
RIGL
Cash + ST InvestmentsLiquidity on hand
$141.1M
$155.0M
Total DebtLower is stronger
$157.0M
$52.5M
Stockholders' EquityBook value
$39.4M
$391.5M
Total Assets
$308.8M
$513.6M
Debt / EquityLower = less leverage
3.99×
0.13×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CMRC
CMRC
RIGL
RIGL
Q4 25
$141.1M
$155.0M
Q3 25
$142.0M
$137.1M
Q2 25
$134.5M
$108.4M
Q1 25
$120.7M
$77.1M
Q4 24
$178.2M
$77.3M
Q3 24
$168.4M
$61.1M
Q2 24
$275.8M
$49.1M
Q1 24
$265.2M
$49.5M
Total Debt
CMRC
CMRC
RIGL
RIGL
Q4 25
$157.0M
$52.5M
Q3 25
$157.3M
$60.0M
Q2 25
$157.5M
$60.0M
Q1 25
$157.8M
$60.0M
Q4 24
$216.5M
$60.0M
Q3 24
$60.0M
Q2 24
$340.9M
$60.0M
Q1 24
$340.5M
$60.0M
Stockholders' Equity
CMRC
CMRC
RIGL
RIGL
Q4 25
$39.4M
$391.5M
Q3 25
$42.8M
$117.6M
Q2 25
$38.8M
$81.9M
Q1 25
$38.1M
$18.6M
Q4 24
$33.4M
$3.3M
Q3 24
$29.0M
$-14.6M
Q2 24
$26.1M
$-29.9M
Q1 24
$26.9M
$-31.7M
Total Assets
CMRC
CMRC
RIGL
RIGL
Q4 25
$308.8M
$513.6M
Q3 25
$309.5M
$242.5M
Q2 25
$302.5M
$206.7M
Q1 25
$286.3M
$176.0M
Q4 24
$340.3M
$164.0M
Q3 24
$335.1M
$139.4M
Q2 24
$452.5M
$128.4M
Q1 24
$442.5M
$126.5M
Debt / Equity
CMRC
CMRC
RIGL
RIGL
Q4 25
3.99×
0.13×
Q3 25
3.67×
0.51×
Q2 25
4.06×
0.73×
Q1 25
4.14×
3.23×
Q4 24
6.49×
18.25×
Q3 24
Q2 24
13.06×
Q1 24
12.65×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CMRC
CMRC
RIGL
RIGL
Operating Cash FlowLast quarter
$980.0K
$22.0M
Free Cash FlowOCF − Capex
$-2.2M
FCF MarginFCF / Revenue
-2.4%
Capex IntensityCapex / Revenue
3.5%
Cash ConversionOCF / Net Profit
0.08×
TTM Free Cash FlowTrailing 4 quarters
$16.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CMRC
CMRC
RIGL
RIGL
Q4 25
$980.0K
$22.0M
Q3 25
$10.6M
$24.0M
Q2 25
$13.6M
$30.5M
Q1 25
$401.0K
$-893.0K
Q4 24
$12.4M
$14.5M
Q3 24
$5.6M
$21.7M
Q2 24
$11.7M
$302.0K
Q1 24
$-3.4M
$-5.0M
Free Cash Flow
CMRC
CMRC
RIGL
RIGL
Q4 25
$-2.2M
Q3 25
$7.6M
Q2 25
$11.9M
Q1 25
$-424.0K
Q4 24
$11.6M
Q3 24
$4.5M
Q2 24
$10.7M
Q1 24
$-4.2M
FCF Margin
CMRC
CMRC
RIGL
RIGL
Q4 25
-2.4%
Q3 25
8.8%
Q2 25
14.1%
Q1 25
-0.5%
Q4 24
13.3%
Q3 24
5.4%
Q2 24
13.0%
Q1 24
-5.3%
Capex Intensity
CMRC
CMRC
RIGL
RIGL
Q4 25
3.5%
Q3 25
3.4%
Q2 25
2.0%
Q1 25
1.0%
Q4 24
0.9%
Q3 24
1.3%
Q2 24
1.3%
Q1 24
1.0%
Cash Conversion
CMRC
CMRC
RIGL
RIGL
Q4 25
0.08×
Q3 25
0.86×
Q2 25
0.51×
Q1 25
-0.08×
Q4 24
1.01×
Q3 24
1.75×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CMRC
CMRC

Subscription And Circulation$65.2M73%
Partner And Services$24.4M27%

RIGL
RIGL

Segment breakdown not available.

Related Comparisons